ALRN vs. TPST, MRNS, CNTB, SPRO, BYSI, CRVS, LFVN, VACC, LPTX, and BRNS
Should you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include Tempest Therapeutics (TPST), Marinus Pharmaceuticals (MRNS), Connect Biopharma (CNTB), Spero Therapeutics (SPRO), BeyondSpring (BYSI), Corvus Pharmaceuticals (CRVS), LifeVantage (LFVN), Vaccitech (VACC), Leap Therapeutics (LPTX), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Aileron Therapeutics (NASDAQ:ALRN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
Aileron Therapeutics received 119 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 66.88% of users gave Aileron Therapeutics an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Aileron Therapeutics currently has a consensus target price of $19.00, suggesting a potential upside of 397.38%. Tempest Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 669.23%. Given Tempest Therapeutics' higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Aileron Therapeutics.
90.9% of Aileron Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 5.6% of Aileron Therapeutics shares are owned by insiders. Comparatively, 3.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Tempest Therapeutics had 5 more articles in the media than Aileron Therapeutics. MarketBeat recorded 10 mentions for Tempest Therapeutics and 5 mentions for Aileron Therapeutics. Aileron Therapeutics' average media sentiment score of 0.95 beat Tempest Therapeutics' score of 0.59 indicating that Aileron Therapeutics is being referred to more favorably in the media.
Aileron Therapeutics' return on equity of -130.32% beat Tempest Therapeutics' return on equity.
Aileron Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.65, suggesting that its share price is 265% less volatile than the S&P 500.
Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aileron Therapeutics beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Aileron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aileron Therapeutics Competitors List
Related Companies and Tools
